

David C Smith

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6924861/david-c-smith-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196
papers

26,599
citations

66
h-index

162
g-index

202
ext. papers

30,570
ext. citations

6
avg, IF

6.5
L-index

#	Paper	IF	Citations
196	ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 502-502	2.2	
195	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2	22
194	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 125, 28-37	8.7	17
193	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
192	Reagent and analyte ion hydrates in secondary electrospray ionization mass spectrometry (SESI-MS), their equilibrium distributions and dehydration in an ion transfer capillary: Modelling and experiments. <i>Rapid Communications in Mass Spectrometry</i> , 2021 , 35, e9047	2.2	5
191	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021 , 7, 525-533	13.4	19
190	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020 , 26, 1247-1257	12.9	29
189	Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS. <i>Clinical Mass Spectrometry</i> , 2020 , 16, 18-24	1.9	19
188	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. <i>Investigational New Drugs</i> , 2020 , 38, 1421-1429	4.3	19
187	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 332-339.e2	3.3	1
186	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1590-1598	8.7	17
185	Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e592-e601	3.3	5
184	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019 , 37, 297-306	4.3	35
183	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019 , 5, 1411-1420	13.4	216
182	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1529-1554	7.3	62
181	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. <i>Cancer Management and Research</i> , 2019 , 11, 10463-10476	3.6	35
180	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. <i>Investigational New Drugs</i> , 2019 , 37, 461-472	4.3	37

179	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018 , 16, 643-654	6.6	24
178	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018 , 35, 21	3.7	3
177	What is the real utility of breath ammonia concentration measurements in medicine and physiology?. <i>Journal of Breath Research</i> , 2018 , 12, 027102	3.1	19
176	Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 8, 189-199	2.2	2
175	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018 , 36, 617-623	2.2	16
174	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1675-1684	2.2	381
173	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 850-858	2.2	184
172	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018 , 36, 3223-3230	2.2	176
171	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018 , 36, 991-999	2.2	117
170	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017 , 7, 620-629	24.4	232
169	Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , 2017 , 22, 369-374	5.7	
168	A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 7490-7497	12.9	106
167	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017 , 86, 296-304	7.5	51
166	A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2017 , 83, 229-236	7.5	20
165	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017 , 548, 297-303	50.4	440
164	On the importance of accurate quantification of individual volatile metabolites in exhaled breath. <i>Journal of Breath Research</i> , 2017 , 11, 047106	3.1	13
163	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017 , 8, 89848-89866	3.3	36
162	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 271-80	3.5	2

161	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8
160	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016 , 1, 59-66	3.3	4
159	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016 , 18, 1-9	6.4	19
158	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 155-62	3.5	50
157	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2016 , 21, 402-3	5.7	2
156	Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 433-41	3.5	10
155	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 851-9	3.5	46
154	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2013-20	2.2	337
153	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015 , 33, 652-63	4.3	32
152	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2004-12	2.2	859
151	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 777-84	3.5	14
150	SIFT-MS and FA-MS methods for ambient gas phase analysis: developments and applications in the UK. <i>Analyst, The</i> , 2015 , 140, 2573-91	5	32
149	Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. <i>European Urology</i> , 2015 , 67, 310-8	10.2	32
148	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
147	Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11057-11057	2.2	1
146	Phase I study of MEDI0639 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3024-3024	2.2	12
145	Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3615-3615	2.2	4
144	Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2531-2531	2.2	1

143	Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. <i>Investigational New Drugs</i> , 2014 , 32, 188-94	4.3	7
142	A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 6295-303 ^{12.9}	11.9	110
141	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014 , 32, 1005-16	4.3	21
140	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1020-30	2.2	1684
139	Small-molecule SMAC mimetics as new cancer therapeutics. <i>Pharmacology & Therapeutics</i> , 2014 , 144, 82-95	13.9	118
138	Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. <i>Bioanalysis</i> , 2014 , 6, 843-57	2.1	50
137	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3391-9	2.2	101
136	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 2684-93	6.4	79
135	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 692-701	6.4	78
134	Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13539-e13539	2.2	2
133	Targeting C-Met/VEGF in Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014 , 265-276		
132	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1089-96	3.5	19
131	Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 412-9	2.2	365
130	A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. <i>Urology</i> , 2013 , 82, 111-7	1.6	26
129	Recent SIFT-MS Studies of Volatile Compounds in Physiology, Medicine and Cell Biology 2013 , 48-76		6
128	Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. <i>Oncologist</i> , 2013 , 18, 163-73	5.7	122
127	On the features, successes and challenges of selected ion flow tube mass spectrometry. <i>European Journal of Mass Spectrometry</i> , 2013 , 19, 225-46	1.1	20
126	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3002-3002	2.2	38

125	Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach. <i>Cancer</i> , 2012 , 118, 44-53	6.4	35
124	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. <i>Investigational New Drugs</i> , 2012 , 30, 249-57	4.3	57
123	Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012 , 30, 749-57	4.3	66
122	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 2443-54	59.2	8684
121	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4505-4505	2.2	5
120	Ambient analysis of trace compounds in gaseous media by SIFT-MS. <i>Analyst, The</i> , 2011 , 136, 2009-32	5	90
119	Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. <i>Urology</i> , 2011 , 77, 1172-6	1.6	12
118	Volatile compounds in health and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011 , 14, 455-60	3.8	33
117	Personalized oncology through integrative high-throughput sequencing: a pilot study. <i>Science Translational Medicine</i> , 2011 , 3, 111ra121	17.5	452
116	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011 , 29, 1432-40	4.3	44
115	Progress in SIFT-MS: breath analysis and other applications. <i>Mass Spectrometry Reviews</i> , 2011 , 30, 236-67	11	250
114	Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. <i>Cancer</i> , 2011 , 117, 2419-25	6.4	11
113	Direct, rapid quantitative analyses of BVOCs using SIFT-MS and PTR-MS obviating sample collection. <i>TrAC - Trends in Analytical Chemistry</i> , 2011 , 30, 945-959	14.6	82
112	Characterization of bone metastases from rapid autopsies of prostate cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 3924-32	12.9	60
111	American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3388-404	2.2	171
110	Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. <i>Journal of Interferon and Cytokine Research</i> , 2009 , 29, 105-12	3.5	19
109	Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2772-8	2.2	30
108	Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. <i>Cancer</i> , 2009 , 115, 4110-7	6.4	101

107	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. <i>Cancer</i> , 2009 , 115, 5541-9	6.4	107
106	The quantification of carbon dioxide in humid air and exhaled breath by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009 , 23, 1419-25	2.2	24
105	Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 511-7	4	55
104	A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). <i>Journal of Urology</i> , 2009 , 181, 2476-80; discussion 2480-1	2.5	53
103	Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. <i>Journal of Breath Research</i> , 2008 , 2, 037013	3.1	110
102	Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. <i>Journal of Urology</i> , 2008 , 180, 2384-8; discussion 2388	2.5	45
101	Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. <i>Journal of Urology</i> , 2008 , 180, 2011-7; discussion 2017-8	2.5	19
100	An exploratory comparative study of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008 , 22, 526-32	2.2	98
99	A selected ion flow tube mass spectrometry study of ammonia in mouth- and nose-exhaled breath and in the oral cavity. <i>Rapid Communications in Mass Spectrometry</i> , 2008 , 22, 783-9	2.2	78
98	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2008 , 113, 975-84	6.4	166
97	Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. <i>Journal of Breath Research</i> , 2007 , 1, 014004	3.1	91
96	Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 318-22	3.3	7
95	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. <i>Cancer</i> , 2007 , 110, 2809-18	6.4	239
94	Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 460-3	3.3	28
93	Living with prostate cancer: patients and spouses psychosocial status and quality of life. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4171-7	2.2	160
92	The concentration distributions of some metabolites in the exhaled breath of young adults. <i>Journal of Breath Research</i> , 2007 , 1, 026001	3.1	40
91	Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2218-24	2.2	288
90	Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 4-83 years. <i>Journal of Breath Research</i> , 2007 , 1, 011001	3.1	71

89	Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. <i>Clinical Genitourinary Cancer</i> , 2006 , 4, 299-302	3.3	63
88	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2006 , 106, 1715-21	6.4	10
87	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. <i>Cancer</i> , 2006 , 106, 2617-23	6.4	4
86	The increase of breath ammonia induced by niacin ingestion quantified by selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2006 , 27, 437-44	2.9	6
85	A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006 , 27, 321-37	2.9	274
84	Generation of volatile compounds on mouth exposure to urea and sucrose: implications for exhaled breath analysis. <i>Physiological Measurement</i> , 2006 , 27, N7-17	2.9	37
83	A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006 , 27, 637-48	2.9	111
82	A longitudinal study of breath isoprene in healthy volunteers using selected ion flow tube mass spectrometry (SIFT-MS). <i>Physiological Measurement</i> , 2006 , 27, 13-22	2.9	106
81	Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. <i>Oncology</i> , 2006 , 71, 168-75	3.6	55
80	Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). <i>Investigational New Drugs</i> , 2005 , 23, 79-84	4.3	58
79	Advances in prostate cancer chemotherapy: a new era begins. <i>Ca-A Cancer Journal for Clinicians</i> , 2005 , 55, 300-18; quiz 323-5	220.7	128
78	Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. <i>Mass Spectrometry Reviews</i> , 2005 , 24, 661-700	11	596
77	Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1439-46	2.2	168
76	Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2540-5	2.2	66
75	On-line analysis of diesel engine exhaust gases by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004 , 18, 2830-8	2.2	22
74	A selected ion flow tube study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with some phenols, phenyl alcohols and cyclic carbonyl compounds in support of SIFT-MS and PTR-MS. <i>International Journal of Mass Spectrometry</i> , 2004 , 239, 139-146	1.9	37
73	Association between Agent Orange and prostate cancer: a pilot case-control study. <i>Urology</i> , 2004 , 63, 757-60; discussion 760-1	1.6	30
72	Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. <i>Urology</i> , 2004 , 64, 69-73	1.6	29

71	Increase of acetone and ammonia in urine headspace and breath during ovulation quantified using selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2003 , 24, 191-9	2.9	39
70	Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-MS study over 30 days. <i>Physiological Measurement</i> , 2003 , 24, 107-19	2.9	170
69	Chemotherapy for localized, high-risk prostate cancer. <i>Seminars in Radiation Oncology</i> , 2003 , 13, 152-157	5.5	2
68	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003 , 98, 269-76	6.4	27
67	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. <i>Cancer</i> , 2003 , 98, 1603-10	6.4	30
66	A SIFT study of the reactions of H ₂ ONO ⁺ ions with several types of organic molecules. <i>International Journal of Mass Spectrometry</i> , 2003 , 230, 1-9	1.9	23
65	Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: results of a pilot study. <i>Psycho-Oncology</i> , 2003 , 12, 814-20	3.9	23
64	Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2003 , 17, 845-50	2.2	115
63	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003 , 61, 774-80	1.6	98
62	Novel gemcitabine-containing triplets in the management of urothelial cancer. <i>Seminars in Oncology</i> , 2002 , 29, 20-4	5.5	12
61	Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 179-85	3.5	7
60	A selected ion flow tube (SIFT), study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of alkenes; in support of SIFT-MS. <i>International Journal of Mass Spectrometry</i> , 2002 , 218, 87-101	1.9	55
59	A selected ion flow tube, SIFT, study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of diols. <i>International Journal of Mass Spectrometry</i> , 2002 , 218, 227-236	1.9	26
58	The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 53, 934-41	4	7
57	Kinetics and isotope patterns of ethanol and acetaldehyde emissions from yeast fermentations of glucose and glucose-6,6-d ₂ using selected ion flow tube mass spectrometry: a case study. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 69-76	2.2	24
56	Analysis of petrol and diesel vapour and vehicle engine exhaust gases using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 1124-34	2.2	38
55	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with the anaesthetic gases halothane, isoflurane and sevoflurane. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 1860-70	2.2	16
54	Quantification of volatile compounds in the headspace of aqueous liquids using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 2148-53	2.2	35

53	On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. <i>Physiological Measurement</i> , 2002 , 23, 477-89	2.9	64
52	Concurrent use of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ precursor ions for the detection and quantification of diverse trace gases in the presence of air and breath by selected ion-flow tube mass spectrometry. <i>International Journal of Mass Spectrometry</i> , 2001 , 209, 81-97	1.9	59
51	Quantitative selected ion flow tube mass spectrometry: the influence of ionic diffusion and mass discrimination. <i>Journal of the American Society for Mass Spectrometry</i> , 2001 , 12, 863-72	3.5	53
50	On-line measurement of the absolute humidity of air, breath and liquid headspace samples by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2001 , 15, 563-9	2.2	70
49	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide. <i>Cancer</i> , 2001 , 91, 2175-80	6.4	6
48	Adjuvant and neoadjuvant therapy in prostate cancer. <i>Seminars in Oncology</i> , 2001 , 28, 3-12	5.5	18
47	A new online method to measure increased exhaled isoprene in end-stage renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 836-9	4.3	64
46	Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. <i>Journal of Urology</i> , 2001 , 165, 56-60; discussion 60-1	2.5	54
45	Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2527-33	2.2	166
44	Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4202-8	2.2	270
43	An investigation of the reactions of H ₃ O ⁺ and O ₂ ⁺ with NO, NO ₂ , N ₂ O and HNO ₂ in support of selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2000 , 14, 646-51	2.2	16
42	Influence of water vapour on selected ion flow tube mass spectrometric analyses of trace gases in humid air and breath. <i>Rapid Communications in Mass Spectrometry</i> , 2000 , 14, 1898-906	2.2	65
41	Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1941-2	9.7	27
40	Trace gases in breath of healthy volunteers when fasting and after a protein-calorie meal: a preliminary study. <i>Journal of Applied Physiology</i> , 1999 , 87, 1584-8	3.7	130
39	Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1664-71	2.2	137
38	A new concept in cancer care: the supportive care program. <i>American Journal of Hospice and Palliative Medicine</i> , 1999 , 16, 713-22	2.6	18
37	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with eleven amine structural isomers of C ₅ H ₁₃ N. <i>International Journal of Mass Spectrometry</i> , 1999 , 185-187, 139-147	1.9	28
36	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several aromatic and aliphatic monosubstituted halocarbons. <i>International Journal of Mass Spectrometry</i> , 1999 , 189, 213-223	1.9	44

35	Phase II trial of suramin in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 1999 , 17, 183-6	4.3	23
34	A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 511-7	3.5	6
33	Selected ion flow tube mass spectrometry: detection and real-time monitoring of flavours released by food products. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 585-596	2.2	109
32	Selected ion flow tube mass spectrometry of urine headspace. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 724-9	2.2	52
31	Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 1354-9	2.2	147
30	Quantification of breath isoprene using the selected ion flow tube mass spectrometric analytical method. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 1733-8	2.2	71
29	Oral chemotherapy in the treatment of hormone-refractory prostate cancer. <i>Drugs</i> , 1999 , 58 Suppl 3, 127-31	12.1	4
28	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. <i>Urology</i> , 1999 , 53, 260-6	1.6	175
27	Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience. <i>Urologic Clinics of North America</i> , 1999 , 26, 333-40	2.9	5
26	Chemotherapy for hormone refractory prostate cancer. <i>Urologic Clinics of North America</i> , 1999 , 26, 323-31	3.9	24
25	All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 41, 133-9	3.5	19
24	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several amines and some other nitrogen-containing molecules. <i>International Journal of Mass Spectrometry</i> , 1998 , 176, 203-219	2.1	66
23	SIFT studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with a series of volatile carboxylic acids and esters. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1998 , 172, 137-147		110
22	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. <i>Urology</i> , 1998 , 52, 257-60	1.6	137
21	Enhancement of 1,25-dihydroxyvitamin D ₃ -mediated antitumor activity with dexamethasone. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 134-41	9.7	86
20	The Selected Ion Flow Tube Method for Workplace Analyses of Trace Gases in Air and Breath: Its Scope, Validation, and Applications. <i>Journal of Occupational and Environmental Hygiene</i> , 1998 , 13, 817-823		36
19	A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. <i>Urology</i> , 1997 , 50, 401-6; discussion 406-7	1.6	75
18	The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. <i>Urologic Clinics of North America</i> , 1997 , 24, 433-7	2.9	7

17	Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. <i>Kidney International</i> , 1997 , 52, 223-8	9.9	265
16	A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 39, 349-56	3.5	46
15	Megestrol acetate in the treatment of hormone refractory prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 308-10	2.7	26
14	The novel selected-ion flow tube approach to trace gas analysis of air and breath. <i>Rapid Communications in Mass Spectrometry</i> , 1996 , 10, 1183-98	2.2	136
13	Application of ion chemistry and the SIFT technique to the quantitative analysis of trace gases in air and on breath. <i>International Reviews in Physical Chemistry</i> , 1996 , 15, 231-271	7	118
12	Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995 , 1, 195-8	2.8	128
11	Population pharmacokinetics of hydroxyurea in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 35, 417-22	3.5	31
10	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 65-8	3.5	18
9	Reactions of Hydrated Hydronium Ions and Hydrated Hydroxide Ions with Some Hydrocarbons and Oxygen-Bearing Organic Molecules. <i>The Journal of Physical Chemistry</i> , 1995 , 99, 15551-15556		98
8	Reactions of H ₃ O ⁺ and OH ⁻ ions with some organic molecules; applications to trace gas analysis in air. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1995 , 145, 177-186		55
7	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 65-68	3.5	
6	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 347-54	3.5	21
5	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 347-354	3.5	
4	A phase I trial of high-dose continuous-infusion hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 33, 139-43	3.5	8
3	Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 31, 363-8	3.5	4
2	Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 272-6	3.5	6
1	Genetic counterselective procedure to isolate interspecific cell hybrids containing single human chromosomes: construction of cell hybrids and recombinant DNA libraries specific for human chromosomes 3 and 4. <i>Somatic Cell and Molecular Genetics</i> , 1986 , 12, 163-74		60